Skip to main content
iNtRON Biotechnology, Inc. logo

iNtRON Biotechnology, Inc. — Investor Relations & Filings

Ticker · 048530 ISIN · KR7048530000 KO Manufacturing
Filings indexed 268 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 048530

About iNtRON Biotechnology, Inc.

https://intronbio.com:6001

iNtRON Biotechnology, Inc. is a biotechnology company specializing in solutions for infectious diseases. Its core activities are centered on three main pillars: bio-new drugs, molecular diagnostics, and molecular biology reagents. The company's therapeutic pipeline focuses on developing novel treatments for drug-resistant super-bacteria, creating antibiotic alternatives and other bio-active agents to address the challenge of antimicrobial resistance (AMR). In its diagnostics division, iNtRON develops and manufactures detection kits and assays, primarily based on real-time PCR technology, for the rapid identification of infectious organisms. The company also provides a range of molecular reagents for research and has commercialized antibiotic alternative products for the animal health market.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is clearly a comprehensive Korean Quarterly Report (“분기보고서”) for the period January 1, 2026 to March 31, 2026, containing detailed financial and operational data, corporate overview, capital changes, and business descriptions. It is not merely an announcement but the full interim/quarterly report itself. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 85% confidence The document is titled “신탁계약해지결과보고서” (Trust Agreement Termination Results Report) and is addressed to the Korean Financial Supervisory Service. It details the termination of a share repurchase trust, the amounts acquired and held, and the relevant dates and figures. This is not an Annual or Interim Report, nor a meeting announcement or dividend notice. It specifically concerns the company’s own share acquisition/disposition via a trust arrangement. According to the category definitions, reports on buying back shares or other own-share transactions fall under “Transaction in Own Shares” (POS).
2026-04-02 Korean
주식소각결정
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement titled “주식소각 결정” (share cancellation decision), detailing the number of treasury shares to be cancelled, total issued shares, cancellation date, and legal basis. This is a corporate action involving a change in capital structure (cancellation of shares), not a repurchase announcement alone nor a full financial report. It falls under the category of share capital changes (issuance, cancellation, stock splits), matching the definition of Share Issue/Capital Change (Code: SHA).
2026-04-02 Korean
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 85% confidence The document is a detailed statutory report to the Korean Financial Supervisory Service on the acquisition of the company’s own shares via a trust contract, including transaction dates, quantities, prices, and cumulative holdings. It is not a director’s personal transaction, capital issuance, or earnings report, but a repurchase of treasury shares under a trust arrangement. This aligns with the “Transaction in Own Shares” category (POS).
2026-04-02 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 90% confidence The document is a Korean Major Event Report (“주요사항보고서”) disclosing the termination of a treasury share acquisition trust contract and the return of cash and shares. It details the company’s own share transaction (treasury stock trust termination, planned share cancellation), fitting the definition of Transaction in Own Shares. Therefore, the correct classification is POS.
2026-04-02 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 80% confidence The document is a formal notification filed to the Financial Services Commission and the Korea Exchange regarding the appointment, dismissal, or mid-term resignation of an outside director (“사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고”). It details the change in board composition, names, dates, and background of the newly appointed outside director. This fits the “Board/Management Information” category (MANG).
2026-03-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.